Validation of Lyophilized Human Fecal Microbiota for the Treatment of Clostridioides difficile Infection: A Pilot Study with Pharmacoeconomic Analysis of a Middle-Income Country-Promicrobioma Project.

Carolina Hikari YamadaGabriel Burato OrtisGustavo Martini BusoThalissa Colodiano MartinsTiago ZequinaoJoao Paulo TellesLuciana Cristina WollmannCarolina de Oliveira MontenegroLeticia Ramos DantasJune Westarb CruzFelipe Francisco Tuon

Published in: Microorganisms (2024)

The lyophilized human fecal microbiota for transplant is safe and can be an important step for a new product with low cost, even with genomic sequencing. Fecal microbiota transplantation emerges as a more cost-effective alternative compared to antimicrobials in the retreatment of CDI.

Keyphrases

endothelial cells
low cost
induced pluripotent stem cells
pluripotent stem cells
clostridium difficile
stem cells
mesenchymal stem cells
copy number
bone marrow
cell therapy
replacement therapy